Loading company…
Pheon Therapeutics develops antibody-drug conjugates for hard-to-treat cancers.
Founded in 2022, Pheon Therapeutics is based in London, UK, and develops antibody-drug conjugates for cancer treatment. Its projects include PHN-010 and PHN-020, both focused on solid tumors. In September 2022, it raised USD 68 million in series A funding led by Brandon Capital Partners, with participation from Atlas Venture, Forbion, and Research Corporation Technologies.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in